Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
- “Why do RAS inhibitors fail to deliver durable responses?
- Why does resistance develop so rapidly to KRAS G12C inhibitors?
A very insightful review revisits these fundamental questions.”
Title: Emerging landscape of KRAS inhibitors in cancer treatment: Cancer Cell
Authors: Jakob Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi Patel, Ferran Fece de la Cruz, Doga Gulhan, Ryan Corcoran
Read the Full Article.
